The trial aimed to show whether aerosolised measles vaccine, given by nebuliser, would result in similar levels of antibodies when compared with the usual subcutaneous injection. The children were all receiving their first dose of measles vaccine at 9 to 11 months of age and living in villages in Pune, in Maharashtra State, India.
Read the article here.
